ClinicalTrials.gg
CompletedNCT00154336Updated Apr 25, 2017

A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.

A Phase 2 interventional study of Imatinib and Methotrexate in Rheumatoid Arthritis, sponsored by Novartis Pharmaceuticals. Completed at 15 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-04-25.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Jul 2004, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Arthritis, Rheumatoid by Novartis — 1 open to participants now, 4 under way, none of them phase 3. Arthritis, Rheumatoid · Novartis.

Enrollment
25th of 30
50 · median 98
Started
2004
with 1 other
Phase 2
9 of 30
none open now
Registered
1st of 30
by date

Among the 30 studies in Arthritis, Rheumatoid by Novartis, this one is the 25th largest by enrollment, is one of 2 that started in 2004, is one of 9 in phase 2, and was the 1st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

1 of the 30 studies in Arthritis, Rheumatoid by Novartis is open now. Recruiting first, the newest first:

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Arthritis, Rheumatoid by Novartis, or all of them as a file.
02

Study summary

Imatinib is a member of a new class of drugs known as signal transduction inhibitors. The purpose of this study is to evaluate the efficacy, safety and tolerability of imatinib in the treatment of rheumatoid arthritis in combination with methotrexate in patients who do not respond satisfactorily to standard treatment, e.g. methotrexate.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid arthritis, imatinib, methotrexate
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • With a diagnosis of RA classified by ACR 1987 revised criteria with symptoms for at least 6 months
  • Functional status class I, II, III according to the ACR 1991 revised classification criteria
  • Patients have to have been treated with MTX at the maximum tolerated dose for at least 3 months, and be on a stable dose and route of administration for at least 2 months prior to study entry
  • Disease activity criteria of minimum 6 out of 28 tender and swollen joints at baseline

Exclusion criteria

Exclusion Criteria:

  • With current use of DMARDs other than MTX. DMARDs include but are not limited to: biologic agents, thiolates (D-penicillamine, thiopronine), sulfasalazine, gold compounds, antimalarials, cyclosporine A, azathioprine, leflunomide and alkylating agents such as cyclophosphamide
  • With any DMRAD treatment used in combination with methotrexate within 1 month prior to study entry. In case of infliximab and leflunomide, a of 2 months is required
  • With any therapy by intra-articular injection, including intra-articular use within 1 month prior to study entry

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Active comparator
    Imatinib 400mmg OD +MTX

    Drug: Imatinib · Drug: Methotrexate

  • Placebo comparator
    Imatinib Placebo + MTX

    Drug: Methotrexate · Drug: Imatinib Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy of imatinib in combination with MTX in pts with active RA by assessing response to treatment(ACR20) after 3 mos compared to MTX alone

  2. Overall safety and tolerability of imatinib in combination with MTX in pts with active RA over 3 mos compared to MTX alone.

Secondary outcomes

  1. Efficacy of imatinib in combination with MTX by assessing the response to treatment (ACR50 and ACR70 criteria; DAS28/EULAR28) after 3 mos compared to MTX alone

  2. Effect of imatinib in combination with MTX on ACR components after 3 mos compared to MTX alone

  3. Effect of imatinib in combination with MTX on rheumatoid factor concentrations

  4. Determine time of onset of clinical response to imatinib in combination with MTX

  5. Determine retention on treatment of imatinib in combination with MTX over 3 mos

  6. Assess pt's quality of life by means of the Euro QoL 50 Health Questionnaire

  7. Assess in a subset of pts pharmacokinetics of imatinib and MTX and their potential interactions when co-administered

  8. Assess pharmacodynamic effect of imatinib in combination with MTX on liver enzymes, hematology and kidney function

  9. Explore potential for RA and drug-specific biomarkers

  10. Explore decrease in synovitis by means of ultrasound in a sub-set of patients.

07

Study locations

15 sites
  • Novartis Investigative site
    Graz, 8036, Austria
  • Novartis Investigative site
    Vienna, A-1090, Austria
  • Novartis Investigative site
    Vienna, A-1130, Austria
  • Novartis Investigative site
    Winnipeg, Manitoba R3A 1M1, Canada
  • Novartis Investigative site
    Toronto, Ontario M5G 1X5, Canada
  • Novartis Investigative site
    Montréal, Quebec H3Z 2Z3, Canada
  • Novartis Investigative site
    Sainte-Foy, Quebec G1W 4R4, Canada
  • Novartis Investigative site
    Helsinki, 00260, Finland
  • Novartis Investigative site
    Husu, 00029, Finland
  • Novartis Investigative site
    Cannock, Staffordshire WS11 2XY, United Kingdom
  • Novartis Investigative site
    Colchester, CO4 5JL, United Kingdom
  • Novartis Investigative site
    Glasgow, G11 6NT, United Kingdom
  • Novartis Investigative site
    Manchester, M41 5SL, United Kingdom
  • Multiple Sites
    Multiple Cities, United Kingdom
  • Novartis Investigative site
    Stoke-on-Trent, ST6 7AG, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2004 to primary completion in Aug 2005, 13 months.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 13 months is below that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 12, 2005
StartActual
Jul 2004
Primary completionActual
Aug 2005
CompletionActual
Aug 2005
Last update
Apr 25, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00154336
Responsible party
Sponsor
First posted
Sep 12, 2005
Start date
Jul 2004
Primary completion
Aug 2005
Completion
Aug 2005
Last update
Apr 25, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion